Tamoxifen for early breast cancer: an overview of the randomised trials

@article{Abe1998TamoxifenFE,
  title={Tamoxifen for early breast cancer: an overview of the randomised trials},
  author={Osahiko Abe and Rikiya Abe and Kohji Enomoto and Kaichiro Kikuchi and Hiroki Koyama and Yasuo Nomura and K Sakai and K. Sugimachi and T Tominaga and Junji Uchino and M. Yoshida and AO van de Velde and J. A. van Dongen and J. B. Vermorken and George Giokas and Byron Lissaios and Vernon J. Harvey and TM Holdaway and R. G. Kay and BH Mason and Alan S. Coates and John F. Forbes and Christian Focan and J P Lobelle and U Peek and G. D. Oates and J. Powell and Michel Durand and Louis Mauriac and Sylvie Bartholomeus and Martine J Piccart and Rebecca S. Gelman and Jay R. Harris and Claire Shapiro and A. K. Hancock and MB Masood and D. Parker and J J Price and S. Jackson and Joseph Ragaz and Thierry Delozier and J. Mac{\'e}-Lesec’h and JL Haybittle and Constance T. Cirrincione and I. Craig Henderson and Ann H. Korzun and Raymond B. Weiss and William Chadwick Wood and M. Baum and Joan Houghton and D. L. Riley and David M. Dent and C A Gudgeon and Amanda Hacking and Km Horgan and Leslie E. Hughes and H. J. Stewart and NH Gordon and HL Davis and Pascale Romestaing and Yves Lehingue and John R. Owen and Paul Meier and Anthony Howell and G. G. Ribeiro and R. Swindell and Juliana Albano and Cf Oliveira and Helena Gerv{\'a}sio and Juliana Olivieri Gordilho and Briguette Carstensen and Torben Palshof and Helge Johansen and S Korzeniowski and Jan Skołyszewski and S. M. Portnoj and Knud West Andersen and C. K. Axelsson and Mogens Blichert‐Toft and Henning T. Mouridsen and Marie Overgaard and Carsten Rose and N. Corcoran and HJ Trampisch and RL Comis and Nancy E Davidson and Richard Gray and Nicholas J. Robert and Douglass C. Tormey and William Chadwick Wood and Jeffrey S. Rossbach and Luc Bijnens and C.J.H. van de Velde and M. Cunningham and Gunther Bastert and Helmut Rauschecker and Rolf Sauer and Willi Sauerbrei and Alfred Schauer and Martin Schumacher and A. de Schryver and Maurizio Belfiglio and E. Mari and Antonio Nicolucci and Nicola Scorpiglione and H. M. Yosef and C S McArdle and Dc Smith and P. C. Lara and Francesco Boccardo and Alessandra Rubagotti and Aura Erazo and JY Medina and Masaru Izuo and Yasuo Morishita and A. E. Bentley and Z. Doran and Ian S. Fentiman and John L. Hayward and R. D. Rubens and Manfred Kaufmann and Walter Jonat and Dietrich von Fournier and George Fountzilas and P Klefstrom and Carl Blomqvist and Jack M Cuzick and Raimund Margreiter and Monica Castiglione and Franco Cavalli and John J. Collins and John F. Forbes and R. D. Gelber and Aaron Goldhirsch and Jurij Lindtner and Karen N. Price and C. M. Rudenstam and Hansj{\"o}rg Senn and Judith M. Bliss and R. Charles Coombes and Michel Marty and Riva Borovik and G. Brufman and Henry Hayat and Elise B. Robinson and Neli Wigler and Franco Pannuti and Shigemitsu Takashima and Tokumitsu Yasutomi and Hiroshi Sonoo and Jun‐ichi Yamashita and Michio Ogawa and Psgj Hupperets and Julien Bonte and Ingrid Tengrup and L. Tennvall-Nittby and P Jovita M Martin and Sylvie Romain and David L. Ahmann and Daniel J. Schaid and Aman U. Buzdar and Terry L. Smith and T Hakes and Larry Norton and Robert Wittes and Robert D. Huerta and MG Sainz and Gianni Bonadonna and Marcella Del Vecchio and Pinuccia Valagussa and Umberto Veronesi and JB Dubois and Angelo Raffaele Bianco and Marc E. Lippman and Lori J. Pierce and Richard Simon and Seth M. Steinberg and James Myles and Joseph L Pater and Kathleen I. Pritchard and Stewart J. Anderson and A M Brown and John Bryant and Joseph Costantino and James J Dignam and Bernard Fisher and Carol K. Redmond and Samuel Wieand and Norman Wolmark and Im Jackson and Michael K. Palmer and James N. Ingle and Vera J. Suman and Nils Olof Bengtsson and L G Larsson and J. P. Lythgoe and Mark W Kissin and Einar Hannisdal and J E Varhaug and Roar Nissen-Meyer and Roger W. Blamey and A. K. Mitchell and John F R Robertson and Y. Nakamura and Gy{\"o}ngyv{\'e}r M{\'a}th{\'e} and J. L. Misset and Hakam Abu-Zahra and E Aileen Clarke and John R McLaughlin and RM Clark and Mark Norman Levine and Ken Morimoto and K. Sawa and Yuichi Takatsuka and Stein Gundersen and Martin Hauer-Jensen and Herman H{\o}st and E Crossley and Adrian L. Harris and Colin Baker and A. Beighton and Mike Clarke and Rory Collins and Christina Davies and T. Elphinstone and Vaughan Evans and Jon Godwin and Emma Greaves and Charlotte Harwood and Abbie Headon and Chindo Hicks and David G. Jackson and Spencer L. James and Edmund Lau and P. A. Mcgale and George C. Mead and Hedda Monaghan and Samuel C. Mozley and Ally Naughten and Richard Peto and Alan John Tooth and K. Wheatley and Patrick Rambert and Bernard Asselain and R. J. Salmon and Jacques R. Vilcoq and Rodrigo Arriagada and Catherine Hill and Agn{\'e}s Laplanche and M. G. L{\^e} and Marc Spielmann and Giorgio Cocconi and Beatrice Di Blasio and Robert Catalano and R Creech and Joni K. Brockschmidt and M. Robert Cooper and O. Andrysek and Jaroslava Barkmanova and Carla I Falkson and M Abraham and Jan G. M. Klijn and A. D. Treurniet‐Donker and Wlj van Putten and Douglas T. Easton and Trevor J. Powles and J-C. Gazet and Vladimir Semiglazov and A. Businico and S. Sardinia and Nagesh Deshpande and L di Martino and Philip Douglas and A. Lindtner and G. Notter and A J Bryant and George H. Ewing and J. L. Krushen-Kosloski and A. Patrick Forrest and W. J. Jack and C. C. McDonald and Torgil R. M{\"o}ller and Stefan Ryd{\'e}n and John M. Carstensen and Thomas Hatschek and Martin S{\"o}derberg and John Carpenter and Kathy S. Albain and James J. Crowley and Stephanie Green and Silvana Martino and C. Kent Osborne and Peter M. Ravdin and L. E. Rutqvist and Arne Wallgren and Lars-Erik Holm and Beat Th{\"u}rlimann and Hermann Brenner and Aleck Hercbergs and M Yoshimoto and Gerrit Deboer and Alexander H G Paterson and J. William Meakin and T. Panzarella and A. Naja and Jacqueline Bahi and Mary Reid and M Spittle and F. Senanayake and Richard R. Love and D. L. de Mets and Jonas Bergh and Lars Holmberg and Paul Sevelda and Christoph Zielinsky and Michael Gnant and Raimund Jakesz and Roger B. Buchanan and G. T. Royle and Janet A Dunn and W. M. Gillespie and K. Kelly and J. M. Morrison and Andrew Litton and R T Chlebowski and Werner Robert Bezwoda and Hans Caffier},
  journal={The Lancet},
  year={1998},
  volume={351},
  pages={1451-1467}
}

Tamoxifen in early breast cancer

WITHDRAWN: Tamoxifen for early breast cancer.

  • M. Clarke
  • Medicine
    The Cochrane database of systematic reviews
  • 2008
The absolute improvement in recurrence was greater during the first 5 years, whereas the improvement in survival grew steadily larger throughout the first 10 years, and the proportional mortality reductions were similar for women with node-positive and node-negative disease, but the absolute mortality reduction were greater in node- positive women.

Tamoxifen and contralateral breast cancer: the other side.

  • S. Swain
  • Medicine
    Journal of the National Cancer Institute
  • 2001
In this issue of the Journal, Li et al. report that they did not find a statistically significant reduction in contralateral breast cancer in women treated with adjuvant tamoxifen, with a hazard ratio of 0.9 (95% confidence interval [CI] 0.7 to 1.2).

Tamoxifen – An Update on Current Data and Where it Can Now be Used

  • L. Wickerham
  • Medicine
    Breast Cancer Research and Treatment
  • 2004
Over the past 30 years, data from a large number of clinical trials have confirmed the efficacy of tamoxifen in estrogen receptor (ER)-positive breast cancer, both as adjuvant therapy and for

Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.

  • K. Pritchard
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
The trial by Boccardo et al, which is published in this issue of the Journal of Clinical Oncology, represents the fourth published randomized trial of an adjuvant aromatase inhibitor used either instead of or after 2 to 3 or 5 years of tamoxifen, and should allow clinicians and patients to make a relatively informed choice regarding the desirability of this treatment.

Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer

  • J. Ingle
  • Medicine
    Clinical Cancer Research
  • 2006
The combined analysis of the Austrian Breast and Colorectal Cancer Study Group 8 trial and the German Arimidex Nolvadex 95 trial, plus the Italian Tamoxifen Anastrozole trial, have shown the advantage of switching to anastroZole over continuing the tamoxIFen to complete the full 5 years of adjuvant therapy.

Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.

Based on the results of these studies, the use of an aromatase inhibitor for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer has largely replaced the previous standard of 5 years of tamoxifen.
...